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Abstract
Embryonic stem cells (ESCs) are pluripotent and have unlimited self-renewal capacity. Although pluripotency and
differentiation have been examined extensively, the mechanisms responsible for self-renewal are poorly understood and are
believed to involve an unusual cell cycle, epigenetic regulators and pluripotency-promoting transcription factors. Here we
show that B-MYB, a cell cycle regulated phosphoprotein and transcription factor critical to the formation of inner cell mass,
is central to the transcriptional and co-regulatory networks that sustain normal cell cycle progression and self-renewal
properties of ESCs. Phenotypically, B-MYB is robustly expressed in ESCs and induced pluripotent stem cells (iPSCs), and it is
present predominantly in a hypo-phosphorylated state. Knockdown of B-MYB results in functional cell cycle abnormalities
that involve S, G2 and M phases, and reduced expression of critical cell cycle regulators like ccnb1 and plk1. By conducting
gene expression profiling on control and B-MYB deficient cells, ChIP-chip experiments, and integrative computational
analyses, we unraveled a highly complex B-MYB-mediated transcriptional network that guides ESC self-renewal. The
network encompasses critical regulators of all cell cycle phases and epigenetic regulators, pluripotency transcription factors,
and differentiation determinants. B-MYB along with E2F1 and c-MYC preferentially co-regulate cell cycle target genes. B-
MYB also co-targets genes regulated by OCT4, SOX2 and NANOG that are significantly associated with stem cell
differentiation, embryonic development, and epigenetic control. Moreover, loss of B-MYB leads to a breakdown of the
transcriptional hierarchy present in ESCs. These results coupled with functional studies demonstrate that B-MYB not only
controls and accelerates cell cycle progression in ESCs it contributes to fate decisions and maintenance of pluripotent stem
cell identity.
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Introduction
All complex organisms contain stem cells with abilities to self-
renew indefinitely and differentiate into one or many types of
specialized cell types. These properties foster organismal develop-
ment and promote cell replacement and organ repair in vivo.
Pluripotent stem cells (PSCs), in particular, differentiate to all cell
types of an embryo proper and may serve as an inexhaustible
source of cell progeny useful for regenerative medicine. The best
characterized and accepted standard for PSCs are embryonic stem
cells (ESCs), which are derived from the inner cell mass (ICM) or
epiblast of the mammalian blastocyst (reviewed in [1]). Experi-
mentally derived PSCs, known as induced PSCs (iPSCs), can also
be generated from somatic cells in vitro through forced expression
of pluripotency-promoting transcription factors that include
OCT4, SOX2, KLF4, c-MYC, LIN28 and NANOG [2,3,4].
Although experimentally-derived PSCs exhibit greater interline
variation and differences in germ-line transmission than ESCs,
iPSC lines may be more immunologically suited for regenerative
medicine and disease modeling [5,6,7,8,9] [10,11].
A defining feature of PSC biology is self-renewal, which can be
aptly defined as the capacity to proliferate indefinitely while
maintaining cell pluripotency [1,12,13,14,15,16]. These two facets
of self-renewal are believed to be intrinsically regulated through
suppression of differentiation by polycomb group complexes
(PcG), histone methylation, the presence of pluripotency tran-
scription factors (TFs) [16], and to a unique ESC cell cycle [17,18].
Importantly, the ability to self-renew is reduced or lost with cell
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commitment and differentiation, but it is re-acquired by somatic
cells reprogrammed to iPSCs. Moreover, a direct link exists
between a cell’s proliferative ability and its capacity for
reprogramming [19]; but, how cell cycle progression and self-
renewal are established and maintained in PSCs is only partially
understood. An improved comprehension of the mechanisms that
control this process will contribute to our understanding of the
biology of self-renewal and the reprogramming of somatic cells to
iPSCs.
Attention to the proliferative component of self-renewal has
focused principally on two key classes of regulatory molecules: a)
cyclins and cyclin dependent kinases (Cdks), and b) proteins that
regulate their assembly and activities [18,20,21,22]. In ESCs,
Cyclins D1, D3, E1, A2, and B1 are present, and except for Cyclin
B, are stably expressed throughout the ESC cell cycle. Cdk activity
is elevated and cell cycle-independent. Characteristically, Cdk inhib-
itory molecules are not expressed, members of the retinoblastoma
(pRb) family are constitutively phosphorylated, and in the absence
of these regulatory proteins, E2F target genes are thought to be
actively transcribed throughout the ESC cell cycle
[18,20,21,22,23]. Contributing to this regulation is the TF c-
MYC [24,25], which is part of a group of factors implicated in the
reprogramming of somatic cells to iPSCs [2,3]. C-MYC contrib-
utes to elevated levels of cyclins D2, E and A; whereas, diminished
levels of c-MYC result in expression of regulatory cyclins and of
cell cycle inhibitors p21Cip1 and p27Kip1 [18,25]. While loss of c-
MYC does not lead to a complete cessation of self-renewal
processes, it causes reduced proliferation and differentiation
defects [25].
Similar to c-MYC, the myeloblastosis oncogene-like 2 (MYBL2)
TF, B-MYB, is critical for inner cell mass formation and ESC
generation [26]. In somatic cells, the mybl2 gene is normally up-
regulated in late G1 and is thought to regulate progression into S
phase. We recently demonstrated that B-MYB is also functionally
implicated in proper progression through the S and G2/M cell
cycle phases of ESCs, as loss of this TF causes replication fork
defects and numerous flaws in mitosis, including severe mitotic
spindle and centrosome defects, and aneuploidy [27,28]. Although
a few B-MYB regulated genes have been identified in somatic cells,
most of the observed defects are mediated through currently
undefined B-MYB target genes. Here, we have examined the role
of B-MYB through genome-wide gene expression profiling,
differential phosphorylation studies, and ChIP-chip experiments
in ESCs and following B-MYB knockdown. These genome-wide
analyses unraveled a complex B-MYB-mediated transcriptional
network that regulates cell cycle progression, and significantly
affects global transcriptional network connectivity, Cdk inhibitory
molecule abundance, and key epigenetic modulators essential to
stem cell identity. Integrated data analysis further demonstrate
that signals responsible for regulating cell cycle progression and
promoting self-renewal traits in ESCs converge through B-MYB.
Results
Knock-down, differential phosphorylation and functional
assays of B-MYB in ESCs
As reported in our previous publication, B-MYB is highly
abundant in ESCs, but here, we show for the first time that it is
also highly expressed in iPSCs at levels similar to those seen in
ESCs (Figure 1A). The functional significance of B-MYB in cell
cycle control of PSCs was demonstrated through the use of short
hairpin RNA (shRNA) constructs in transient knockdown exper-
iments [27]. In this study, we principally employed shRNA1,
which provided highly consistent functional results comparable to
those found with either shRNA2 or shRNA5; however, these latter
shRNAs were employed for validation experiments [27]. Consis-
tent with our previous findings with shRNA1, 2 and 5, B-Myb
RNA levels and B-MYB proteins levels were routinely decreased
by .90% and by .70%, respectively (n = 8 for each condition).
Knockdown of B-Myb resulted in small colonies consisting of
fewer ESCs than that found in controls. These data are quantified
in graphic form in Figure 1B. The number of cells within each
colony that incorporated bromodeoxyuridine (BrdU) during S
phase was also significantly reduced (p,0.05). Most BrdU
negative cells in the knockdown experiments have slightly enlarged
nuclei relative to controls, indicating some degree of cell
differentiation. This finding is consistent with our previous report
showing increased expression of differentiation markers CoupTF,
Fgf5, Sox17, Cdx2 and Hand1 following knockdown of B-MYB
[27] (Figure 1C). Knockdown of B-MYB also caused a significant
increase in aneuploid cells with 8N chromosome content and an
increased number of cells in G2/M with a corresponding decrease
in G1 phase cells (Figure 1D), which we have quantified for the
first time in Figure 1E. At a cellular level, a significant increase in
monopolar and multipolar centrosomes with spindle defects was
reconfirmed, showing that loss of B-MYB leads to profound cell
cycle abnormalities (Figure 1F).
Post-translational phosphorylation of B-MYB does not account
for the phenotypic changes observed in ESCs following knock-
down. In somatic cells, hypo-phosphorylation is associated with
increased B-MYB stability and activity [29], while site-specific
phosphorylation in the conserved region and the negative
regulatory domain of this protein results in altered transcriptional
activity [30,31,32,33,34]. In ESCs, we show that B-MYB under-
goes site specific phosphorylation in a cell cycle-dependent manner
(Figure 1G–1H) that does not differ between control and
knockdown conditions. In ESCs, phospho-Ser581, which is
associated with transcriptional repression, was undetectable (not
shown), but phosphorylated forms of Thr490 and Thr497, which
are associated with transcriptional activation, were observed in
,5–20% of the ESCs. These latter results are consistent with the
post-translational modifications that we previously observed by
two-dimensional gel electrophoresis [27]. In this study, phospho-
Thr490 and phospho-Thr497 were only observed in the G2/M
phases of the cell cycle (Figure 1H). B-MYB translocation to the
extra-chromosomal space during late mitosis and cytokinesis was
also preceded by phosphorylation, as mitotic cells were always
phosphorylated (immunostaining in Figure 1G) and the numbers
of mitotic cells correlated directly with the phosphorylated forms
of B-MYB observed by flow cytometry (Figure 1H, boxed regions).
Importantly, the number of cells with phospho-Thr490 or
phospho-Thr497 B-MYB did not increase in proportion to the
overall increase in cells present in the G2/M phases of the cell
cycle following KD of B-MYB. This result suggests that B-MYB
phosphorylation occurs primarily during late G2 or early M phase,
since cells lacking B-MYB appear to be blocked in the early G2
phase of the cell cycle [27]. B-MYB is therefore hypo-phosphor-
ylated in a majority of control ESCs; however, phosphorylation at
sites Thr490 and Thr497 in late G2 or early M phase is oscillatory
and intrinsic to the unusual cell cycle and self-renewal properties of
ESCs.
Knockdown of B-MYB causes a significant but transient
decrease in the accumulation of known somatic cell B-MYB
target gene products (Ccnb1, Cdca2 and Plk1) implicated in
normal progression from G2 into M phases of the cell cycle. In
Figure 2A, we show that the abundance of CCNB1 protein is
reduced 48 hours after nucleofection regardless of the shRNA
employed to knockdown B-MYB (shRNA1: 64%; shRNA2: 57%;
B-MYB Transcriptional Networks in Stem Cells
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Figure 1. B-MYB function and phosphorylation in pluripotent stem cells. A) Western blot showing presence of B-MYB in ESCs (R1) and iPSCs
(2D4). B) Graphic representation of the average number of cells present within individual ESC colonies (n = 40 colonies/group) 48 hours after
nucleofection with control or targeting shRNA1 vectors to B-MYB. C) Typical image of pulsed BrdU incorporation in control and B-MYB deficient ESCs,
showing decreased BrdU incorporation in B-Myb knockdown (KD) cells. D) DNA content measured by flow cytometry of non-synchronized fixed ES
cells stained with propidium iodide after nucleofection with shRNA constructs. At 48 hours post-nucleofection, including 24 hours of selection with
puromycin, a shift in the DNA content to a G2/M prevalent and aneuploid (8N) state (see arrows in inset) can be detected. E) Quantification of the cell
cycle distributions following knockdown (KD) of B-MYB. The number of cells in S phase decreased concomitant to an increase in the number of cells
in G2/M relative to controls and a significant increase in octoploidy (8N). F) Representative mitotic cells stained with DAPI (blue), a-tubulin (green) and
c-tubulin (red) are shown. In these experiments, mitotic spindle and centrosome defects are readily observed in cells lacking B-Myb. A quantitative
assessment of spindle defects detected in B-Myb deficient cells (n = 3, 100 cells/group) is shown in the graph below. G) Images of immunostained ESC
colonies with antibodies specific for phosphorylated forms of B-MYB. It is noteworthy that all mitotic cells show phosphorylation at Thr490 or Thr497.
B-MYB Transcriptional Networks in Stem Cells
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and shRNA5: 41% relative to controls). CCNB1 protein levels
remained significantly reduced 24 hours later; however, RNA
expression levels returned toward control levels at this later time
point (data not shown). Similar results were observed for Plk1.
RNA levels were significantly reduced at 48 hours but not
72 hours post-nucleofection. In contrast, protein levels of PLK1
were significantly reduced at both time points (Figure 2B). Similar
results were seen with CDCA2 (not shown), and we previously
reported that Oct4 and Sox2 had comparable expression patterns.
Based on these and subsequent analyses (see below), we conclude
that transient but significant changes in RNA expression
represented a common feature of this knockdown model system.
To determine if reduced expression of Ccnb1 could account for
the B-MYB phenotype, as was the case for the zebrafish crash&burn
(crb) mutant [35], we employed a microRNA-mediated knock-
down strategy that reduced Ccnb1 to comparable levels (60–80%
of controls) present in B-MYB knockdown cells (Figure 2C). In
these experiments, no significant differences could be demonstrat-
ed in the total number of cells present per colony, BrdU
incorporation, the number of cells in G2/M (not shown), or
Oct4 expression levels; however, decreased Ccnb1 caused a
significant but modest reduction in B-Myb transcripts (p,0.05,
n = 4, Figure 2C). Even when Ccnb1 transcripts were reduced by
,80%, we were unable to detect any evidence of polyploidy,
spindle defects or other cell cycle abnormalities (Figure 2D). These
results show that, at least in mammalian-derived ESCs, B-MYB
leads to cell cycle defects that cannot be fully explained by
phosphorylation or the actions of a single known downstream B-
MYB target gene that is required for progression through G2/M
in somatic cells.
Alteration of gene expression by B-MYB knockdown
Having established a robust and reproducible model system to
knockdown B-MYB in mouse ESCs, genome-wide RNA expres-
sion analyses were performed to determine which genes respond to
the transient loss of B-MYB. Normalized expression data revealed
that B-MYB significantly regulates the expression of 5.5% and up
to 18.6% of the ,25,600 well-annotated RefSeq transcripts
present on the Illumina BeadChips. In these experiments,
,18,000 transcripts were expressed at levels above background
in both experimental conditions. A total of 4,768 (18.6%) and
1,407 (5.5%) gene transcripts exhibited $1.5 and $2.0 fold
differences in abundance, respectively between control and B-
MYB-deficient ESCs. Among those transcripts with $1.5 abun-
dance changes, .95% of the transcripts displayed elevated
expression in control ESCs (4,554) relative to those lacking B-
MYB. Only 214 mRNAs had increased abundance in the B-MYB
deficient cells (Figure 3A, Table S1).
We employed gene set enrichment analysis (GSEA) [36] and
Fisher’s exact tests to identify biological processes and pathways
significantly over-represented in differentially expressed gene sets.
A total of 51 enriched KEGG pathways were affected by loss of B-
MYB (p,0.05 and FDR q,0.25) (Table S2A). The most
significantly enriched biological processes were associated with
cell cycle, mitosis and mitotic regulation, chromosome organiza-
tion and biogenesis, and DNA repair and replication (Table 1). For
those genes that showed increased expression following B-MYB
knockdown, the biological processes that were most affected are
reported in Table S2B, and include cellular defense response,
synaptogenesis, cyclic nucleotide mediated signaling and ion
transport. Figures 3B and 3C illustrate a GSEA of cell cycle (the
most affected pathway) and insulin signaling pathways. Of 103
genes in the cell cycle pathway, 65 were down-regulated (.1.5-
fold) following B-MYB knockdown, while 4 were up-regulated,
including two inhibitory proteins normally absent in ESCs. Many
of the transcripts with reduced abundance encode proteins that
regulate G1 to S and G2 to M transitions. GSEA further revealed
that TFs E2F, E2F1, E2F1-DP1&2, and E2F4-DP1&2 were
significantly enriched (p= 0, FDR q=0) in gene sets with reduced
expression (Table S3), while knockdown of B-MYB specifically
reduced the expression (.1.5 fold) of E2F1-E2F5, DP1, and DP2
(Table S1). B-MYB deficiency also altered the core transcriptional
program mediated by Oct4, Sox2 and Nanog. These gene
products were reduced by 60%, 58% and 46% respectively, while
that of B-MYB was reduced by .80% in this experimental set. B-
MYB deficiency also significantly reduced expression of key factors
that regulate self-renewal and differentiation including those from
genes encoding pluripotency-associated TFs (e.g. Tcf3, Tcl1,
Esrrb, Zfp281, Zic3, Ctcf, E2f1), Polycomb repressive complex-2
(PRC2) core components (Eed, Ezh2 and Suz12) and co-binding
proteins (Jarid2), PcG genes (Phc1 and Rnf2), DNA methyltrans-
ferase Dnmt3b, H3K9 demethylase Jmjd2c, and reprogramming
factors (Lin28) (see Table S1)(see reviews [37,38,39,40]).
To validate the microarray results, we selected 17 transcripts,
including B-Myb, with altered expression, and quantified their
abundance by qPCR in independent experiments (n = 3). To
ensure against non-specific effects associated with the use of
shRNA1, RNA was prepared from cells nucleofected with
shRNA1, 2 or 5. As shown in Figure 3D, the vast majority of
the transcripts showed transient changes in expression within
48 hours (24 hours of puromycin selection) of B-Myb KD. At
72 hours post-nucleofection, most of the transcripts (15 of 17),
regardless of the shRNA employed, returned towards control
levels, consistent with what was shown in Figure 2 for Plk1. Two
exceptions were noted. P21Cip1 increased in response to knock-
down by shRNA1, but it did not show significant increases in
abundance with either shRNA2 or shRNA5 at either 48 or
72 hours. Dbf4 mRNAs transiently decreased in abundance
following B-Myb knockdown by shRNA1 and shRNA2, whereas
only a sustained decrease was observed with shRNA5. These data,
while largely confirmatory of the expression patterns determined
by microarray, show that some differences in gene expression may
be attributable to non-specific effects associated with shRNA1.
Intra-pathway transcriptional modulation by B-MYB
Modular behaviors of gene expression are useful at uncovering
cellular mechanisms implicated in functional control. By exten-
sion, co-expression gene clusters are informative of transcriptional
modulation. Figures 4A–4B illustrate the identification of co-
expression clusters in the cell cycle pathway, where we identified 2
co-expression clusters in control (C1 and C2) and in B-MYB
knockdown (K1 and K2) cells, respectively. We also uncovered 2
conserved and overlapping co-expression clusters, O1 and O2
(Table 2, Table S4A). Within the cell cycle network, a number of
genes showed conserved co-expression patterns, which were
unchanged after B-MYB knock-down. These conserved co-
expression modules included inhibitory genes like cyclin-depen-
dent kinase inhibitors (Cdkn2b, Cdkn2d, Cdkn1b and Cdkn1c)
H) Flow cytometry analysis of mouse ESCs showing that phosphorylated forms of B-MYB are present only in the G2/M phases of the cell cycle (see
boxed region). The number of cells present in the boxed regions correlates directly with the number of red mitotic cells shown in the inset of
Figure 1G. Size marker = 15 mm. *, p,0.05. Data are expressed as mean 6 standard deviation (SD).
doi:10.1371/journal.pone.0042350.g001
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Figure 2. Examination of known somatic cell B-Myb target gene expression patterns following knockdown of B-Myb in ESCs. A)
Western blot and graphic presentation of Cyclin B1 (Ccnb1) protein expression following knockdown of B-MYB by shRNAs 1, 2 and 5. B) RNA (left) and
protein (right) analysis of the B-MYB target gene Polo-like kinase 1 (Plk1) following Bc-Myb KD with shRNA1 and shRNA5. The effects of B-MYB KD on
Plk1 RNA were transient; however, the loss of RNA led to a significant and sustained decrease in its protein abundance. C) Western blot and bar graph
showing the abundance of selected proteins following knockdown of B-MYB and CCNB1 using shRNAs and microRNAs, respectively. D) Reduced
B-MYB Transcriptional Networks in Stem Cells
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and cyclin D inhibitor Gsk3b in G1 and S, and cyclin inhibitors
(Gadd45A-B, 14-3-3s) and Wee1 in G2 and M phases (Table
S4A), indicating that B-MYB does not directly impact the co-
regulation of these core inhibitory genes in ESCs. In contrast,
numerous cell cycle core members showed divergent co-expression
patterns, where genes showed unique relationships depending on
the experimental condition. For example, under conditions where
B-MYB is normally expressed (i.e., controls), transcriptional co-
expression was observed among G1/S associated cyclin D1, kinase
Cdk2 and their targets Tfdp2 and Rbl1 (p107); Trp53 and its
target gene Cdkn1A (p21Cip1); and the G2/M transition protein
Gadd45G that inactivates the cdc2-cyclin B complex. This co-
expression pattern was not, however, maintained in B-MYB
deficient cells (Figure 4C). Similarly, Ccne1 and Ccne2, E2f1,
Skp1a, and Ccna1 during G1/S transitions, as well as the p53
cofactor CBP/p300 were co-regulated in normal cells, but
uncoupled in B-MYB deficient cells (Table S4A). This divergent
co-expression pattern indicates that B-MYB significantly modu-
lates the transcriptional- and co-regulation among core cell cycle
elements.
expression of CCNB1 could not mimic the cell cycle related defects associated with B-MYB deficiency, such as monopolar or multipolar centrosomes
as described in Figure 1. Ctl – control; KD – Knockdown; NS- non-silencing. *, p,0.05. Data are expressed as mean 6 standard deviation (SD).
doi:10.1371/journal.pone.0042350.g002
Figure 3. Pathway enrichment analysis. A) Hierarchical clustering of differentially expressed genes (fold-change $1.5) in control and B-MYB
deficient cells. Red and green colors denote increased and decreased expression, respectively. Each row represents a unique experiment (n = 4, ctl
and n=4, KD) B) KEGG pathway enrichment among the B-MYB knockdown-repressed genes. The enrichment profiles for cell cycle and insulin
signaling pathways for genes with reduced expression in B-MYB deficient cells are shown. C) Heatmaps showing gene expression in cell cycle and
insulin signaling pathways, indicating that the majority of transcripts are decreased (blue) in abundance in the absence of B-MYB. D) Confirmation of
shRNA1 specificity and qPCR analysis of selected cell cycle products and epigenetic regulators. Most of the transcripts analyzed by qPCR showed
consistent trends in expression after nucleofection with shRNA1, shRNA2 or shRNA5. Exceptions included Cip1 and Dbf4, both of which had
unexpectedly low transcript levels with shRNA5 relative to shRNAs 1 and 2. Almost all of the transcripts with decreased expression 48 hours after
nucleofection had modest to significant increases in mRNA expression 24 hours later.
doi:10.1371/journal.pone.0042350.g003
B-MYB Transcriptional Networks in Stem Cells
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Apoptosis genes also showed considerable change in transcrip-
tional co-expression in response to B-MYB deficiency, consistent
with our previous report of apoptosis [27] (Table S4B). Among 78
apoptosis genes examined, 20 were significantly down-regulated
while only 4 were up-regulated in B-MYB deficient cells. Both
apoptotic (Apaf1, Atm and Casp9) and anti-apoptotic (Birc2, Rela
and Irak) genes showed conserved co-expression. The ligands
Tnfa and Fasl and their receptor Tnfsf1a however showed
divergent co-expression, as did Trp53, and pro-apoptotic (Bid,
Casp3, 6–8) and anti-apoptotic (Bcl-xl and Bcl-2) transcripts
(Table S4B). Some important apoptotic genes (i.e. Trp53,
Casp3&6, and Bid) were significantly down-regulated by the loss
of B-MYB and were co-expressed in a divergent pattern.
Moreover, p53 target genes Bbc3 and Perp showed co-expression
in B-MYB knockdown cells but not in control cells. B-MYB
deficiency therefore has a broad impact on co-expression patterns
of pro-apoptosis and anti-apoptosis genes, and is actively involved
in the transcriptional modulation of apoptotic genes in ESCs.
Transformation of the global transcriptional network by
B-MYB knockdown
We constructed global co-expression networks based on
transcriptional correlations (i.e., expression patterns) from all
genes expressed in normal (16,058 genes) and B-MYB deficient
ESCs (16,143 genes), respectively. The resulting networks,
composed of nodes (i.e, genes) and links (i.e, co-expression
between genes), showed scale-free topology (Figure S1), indicating
that each was dominated by a small set of highly-connected genes
(hubs) that link less connected genes to the system (Table S5).
Strikingly, most of the hub genes in the co-expression network of
B-MYB deficient cells differed from the hub genes of controls
(Table S5A–D). As an example, B-Myb functions as a hub gene in
control cells, but in B-MYB deficient cells, it no longer functions as
a hub gene. Among the 300 most prominent hub genes in each
network, only 51 genes were in common, while among the top 100
hub genes, only 1 gene was present in both networks. This lack of
hub similarity indicates that B-MYB is critical to the maintenance
of essential biological functions in ESCs.
Many of the network genes, including hub genes, showed
considerable changes in connectivity (i.e. the number of links to
each gene) in response to B-MYB knock-down (Table S5C,D).
Altered connectivity was particularly important to genes encoding
TFs (Sox2, Lin28, Klf4), epigenetic regulators (Phc1, Eed, Ezh2),
and signaling molecules (Tcf7, E2f1, Smad3) involved in ESC
developmental processes. For example, B-Myb, Eed and Sall4
were among the top 300 hub genes in control ESCs, but following
knockdown, their connectivity, and consequently functional
importance, were significantly reduced (Figure 5A). In contrast,
the network connectivity of the cell cycle regulatory gene c-Myc
and pluripotency factor Klf4 significantly increased; however,
none of these factors remained among the top 300 hub genes of B-
MYB deficient cells. The single TF hub gene with the largest
change in connectivity was Sall4, even though its expression
increased following B-Myb knockdown. It was connected to a total
of 959 genes in normal cells, while no links remained in B-MYB
deficient cells (Table 3). Similarly, Sox2 and Lin28 showed a
dramatic reduction in their connectivity; but unlike Sall4
(Figure 5B), these gene products were reduced in response to B-
MYB knockdown. Other examples of hub genes present in control
but not B-MYB deficient cells included hedgehog pathway gene
Table 1. Biological processes and pathways associated with B-MYB deficiency.
Biological process of gene ontology (GO) Gene number P value FDR q-value
Cell cycle 271 0 0
Cell cycle phase 148 0 0
Cell cycle process 169 0 0
Chromosome organization and biogenesis 104 0 0
DNA repair 112 0 0
DNA replication 85 0 0
M phase 101 0 0
M phase of mitotic cell cycle 75 0 0
Microtubule cytoskeleton organization and biogenesis 30 0 0
Mitosis 73 0 0
Mitotic cell cycle 134 0 0
Protein RNA complex assembly 54 0 0
RNA processing 148 0 0
Translation 147 0 1.45E-04
Protein folding 49 0 1.84E-04
Cellular component assembly 261 0 7.17E-04
Interphase of mitotic cell cycle 52 0 7.63E-04
Golgi vesicle transport 42 0 0.001252277
Intracellular transport 242 0 0.002075577
Regulation of cell cycle 155 0 0.002068629
A total 18,097 genes were ranked by fold-change of gene expression between control and B-MYB knockdown in mouse ESCs based on microarray experiments (see
Methods). Ranked genes were analyzed using GSEA based on GO biological processes. The biological processes in the table represents enriched ones with P value of 0
for under-expressed genes by B-MYB knockdown.
doi:10.1371/journal.pone.0042350.t001
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Figure 4. Identification of conserved and divergent co-expression gene clusters in the cell cycle. A) Graphic representation of a
correlation matrix of genes based on expression profiles in control (the lower-left triangle) and B-MYB knockdown (the upper-right triangle) ESCs.
Genes are listed on the horizontal and vertical axes in the same order. Clustering profiles were determined from the correlation of gene expression
where control samples were used as the primary reference. C1 and C2 represent co-expression clusters in controls. The light-to-dense color gradient
on the graph indicates low-to-high correlations between gene and their expression. B) Clustering analysis based on the correlation of gene
expression where B-MYB deficient (knockdown) samples were employed as the primary reference. K1 and K2 represent co-expression clusters in
knockdown conditions. C) Core network illustrating expression and co-expression patterns in a KEGG cell cycle pathway.
doi:10.1371/journal.pone.0042350.g004
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Smo, apoptotic Igfbp3, anti-apoptotic Bcl-xl, Wnt and TGFb
pathway genes Ppp2r1a and Ppp2cb, Wnt genes Chd8 and
Nfact4, and notch receptor Notch3. While B-MYB deficiency
decreased network connectivity on those genes, it increased the
network connectivity of pluripotency regulators c-Myc, Klf4, Tcf3,
Ezh2, Jmjd1a, Rnf2, and Dnmt3b (Table 3). B-MYB deficiency
did not, however, significantly alter network connectivity of
pluripotency factors Oct4 and Nanog, even though the expression
level of both was significantly reduced.
Finally and when assessing changes in connectivity, it is
important to realize that connectivity is not necessarily correlated
with the magnitude of a fold change determined by gene
expression analyses. Our microarray data specifically demonstrat-
ed that B-MYB knockdown results in differential gene expression
and fold changes in RNA, i.e., how B-MYB influences the
expression of individual genes. In contrast, connectivity shows gene-
gene relationships in terms of co-expression patterns under two
conditions. A high value of connectivity indicates how many genes
may be linked with a gene based on a similar expression pattern.
Table 3 clearly shows that several important ESC regulators (e.g.
Sox2, Lin28, Tcl1, Esrrb, Ezh2, Dnmt3b) show consistent changes
in fold change and in connectivity, while other genes (e.g., Oct4
and Nanog) show alternation in one but not the other.
B-MYB target genes by ChIP-chip identification
To identify B-MYB target genes that could account for the cell
cycle abnormalities and changes in gene transcription described
above, chromatin immunoprecipitation (ChIP-chip) experiments
were performed. An example of B-MYB binding sites along
Chromosome 6 is illustrated in Figure 6A. The data revealed that
up to 8.2% of known promoters in the mouse genome bound B-
MYB. Four independent analyses of R1 ESCs identified a total of
2250 promoter regions that bound B-MYB in at least one sample,
1020 promoters in 2 samples, 482 promoters in 3 samples, and 184
promoters in all 4 samples (Table S6). A number of individual
gene promoters bound B-MYB in more than one discrete site (i.e.,
Sox2); whereas the majority bound B-MYB at only one location or
on closely overlapping ‘‘tiles’’. In B-MYB deficient cells, the
number of detectable promoter sites that bound B-MYB above
threshold was reduced by 77.1% relative to controls (CHiP-chip),
and a 60% reduction was observed in the total number binding
events detected for two control genes Cdca2 and Ccnb1 by CHiP
(Figure 6B). Antibody immunoprecipitation of B-MYB chromatin
binding was therefore highly specific and significantly reduced in
B-MYB deficient cells. The results further revealed that pluripo-
tency genes sox2 and nanog bound B-MYB, but no binding to the
promoter of pou5f1 (Oct4) was observed. Independent ChIP assays,
where data were normalized using an independent IgG based
technique, confirmed binding of B-MYB to the promoter regions
identified by ChIP-chip for sox2 (two sites), nanog, ezh2 and lamb2,
among others (Figure 6C). Importantly, most B-MYB target genes
were primarily associated with biological processes corresponding
to those observed from the transcriptome-based study described
above, strongly suggesting that the changes in RNA abundance
were directly attributable to altered transcriptional activity
mediated by B-MYB (Table 4 and Table S7).
Computational analysis of the promoter sequences that bind B-
MYB identified 50 consensus cis-elements, whose presence differs
significantly from predicted values (P#0.01) (Table S8). The most
over-represented cis-elements (Z-score = 21.54) corresponded to
the cellular and viral myb-like transcriptional regulators (mybl
binding sites), which was present in a total of 1540 (61%) input
sequences. Cis-elements to E2F-myc activator/cell cycle regulator
(Z score = 6.52), SOX/SRY-sex/testis determining and related
HMG box factors (Z score = 6.93) and paralog hox gene (Nanog)
binding factors (Z-score = 7.85) were significantly over-represent-
ed, as were cis-elements to homeodomain- and homeodomain
leucine zipper TFs (Table S8). Cis-elements to E-box binding
factors like C-MYC (Z score =26.29) were significantly under-
represented in promoters that bind B-MYB. No single binding site
was conserved among all identified gene promoters, and among
the B-MYB bound promoters, almost half did not contain an
IUPAC consensus mybl binding site; however, a potentially novel
IUPAC consensus sequence of NAAAANAAAN was present in
76% of the promoters.
Integrative analyses of ChIP, microarray and methylation
data
Integrative analysis of gene expression, TF binding and
epigenetic data is a powerful approach for determining functional
relationships in gene networks. We, therefore, identified an
informative gene set based on the overlap between B-MYB
Table 2. Identification of co-expression gene clusters in ES cell critical pathways.
Pathway
No of genes
in the pathway
Co-expression
cluster
No of genes in
the cluster
Average r
(correlation coefficient)
No of differentially expressed genes
in the cluster (under-/over-expressed
by B-MYB knockdown)
Cell cycle 116 C1 30 0.735 18/0
C2 32 0.776 16/3
K1 30 0.747 19/0
K2 36 0.767 16/1
O1 21 0.718(ctl)/0.738(kd) 11/0
O2 19 0.838(ctl)/0.777(kd) 8/1
Apoptosis 78 C1 28 0.719 6/0
C2 16 0.716 2/0
K1 28 0.669 4/0
O1 15 0.717(ctl)/0.816(kd) 2/0
C1–2 and K1–2 represent co-expression clusters identified in the ES cells of control and B-MYB knockdown, respectively. O1–2 represents conserved co-expression
clusters cross the control and B-MYB knockdown. Ctl: ES cell control, kd: ES cells with B-MYB knockdown.
doi:10.1371/journal.pone.0042350.t002
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binding targets and whole-genome expression data. Among 1020
B-MYB target genes identified by ChIP-chip and present on
microarrays, 775 (76%) were expressed in ESCs at levels equal to
or above threshold. 361 were differentially expressed by at least
1.5-fold, and 96% of differentially expressed genes showed
reduced expression following B-MYB knockdown (Table S9).
The most prominent biological processes associated with this
informative set centered on mitosis and cell cycle regulation, but
morphogenesis, cell fate commitment, and differentiation were
also significantly enriched (Table 4). Conclusively, cell cycle genes
were significantly over-represented (P= 1.7161024, FDR=0.20).
Notably, 16 of 361 differentially expressed B-MYB target genes
belonged to the cell cycle pathway and included G1 proteins
Ccnd1, Cdk6 and Trp53, and G2/M proteins Ccnb1, Cdc25c,
Wee1, Plk1, and Bub1b. Apoptosis pathway genes (Trp53, Birc2,
Casp3), pluripotency factor genes (Sox2 and Nanog), PcG gene
Phc1, core PRC2 component Ezh2 and its co-binding protein
Jarid2, and H3K9 demethylase Jmjd2c were also present in this
informative and differentially expressed target gene set (Table S9).
Transcript abundance was highly variable among the informative
775 B-MYB target genes (Figure 6D).
To better define how B-MYB target genes are regulated in
ESCs, we identified genes co-targeted by B-MYB, OCT4, SOX2
and Nanog (OSN, Figure 7A and Table S1). We determined that
35–41% of the B-MYB target genes bound OSN, 166 of which
(16%) bound multiple pluripotency TFs (p,0.05), and 53 target
genes were putatively regulated by all four TFs (Figure 7B), (e.gs.,
zfp42, sox2, nanog, trp53, phc1 and jarid2 (Table S1)). Genes, like
ezh2, bound B-MYB, OCT4, and SOX2, but not NANOG, while
fbxo8 and tuba1a only bound B-MYB. Co-targeted genes were
significantly associated with stem cell differentiation, embryonic
development, regulation of transcription, and epigenetic control;
however, cell cycle-related proteins, while present, were under-
represented among the informative co-targeted gene set
(Figure 7A). Consistently, many of the genes that bound only B-
MYB included cell cycle pathway specific genes (Table S10), as
well as cell-cycle associated proteins involving mitosis, centrosome
and spindle formation, DNA and RNA polymerases, and
ubiquitin-specific peptidases (Figure 7B, Table S1). B-MYB,
therefore, co-targets a set of genes bound by multiple pluripotency
TFs, and it has unique targets that are not regulated by OSN.
Figure 5. Global network analysis showing the distribution of connections per node in the co-expression networks. A) Interactome
showing hub genes and connectivities among hubs of selected pluripotency, cell cycle and epigenetic regulator-associated genes in control (Ctl) and
B-Myb knockdown (KD) cells. The size of each circle is directly proportional to the number of links (connectivity) for the indicated hub gene, and lines
between genes are indicative of the number of overlapping links. As shown in this figure, B-Myb, Eed and Sall4 are major hub genes in control cells
that have overlapping links with over 160 genes. Following knockdown of B-MYB, all of major hub genes either become minor hubs or lose all
connectivity (shown in red). B) Based on the analysis, Sall4, a transcription factor found to be central to the control ESC network, loses all connectivity
in B-MYB deficient ESCs (4A); but in response to the loss of B-MYB, Sall4 transcript and protein abundance increase significantly, suggesting that the
up-regulation of this gene is a compensatory response to the loss of B-MYB.
doi:10.1371/journal.pone.0042350.g005
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When compared with 15 other TFs implicated in self-renewal
and pluripotency, the largest intersection of target genes was with
E2F1 (61%) (Tables S1 and S10). This TF bound to all 16 B-MYB
target genes associated with cell cycle regulation, including those
that did not bind OSN. We have not, however, been able to detect
any direct physical interaction between B-MYB and E2F1 in ESCs
by immunoprecipitation, Western or mass spectrometry (not
shown). Similarly, c-MYC bound to 22.5–35.2% of the B-MYB
targeted genes, including bub1b, ccnb1, and plk1 (Table S1).
Altogether, c-MYC bound to 42 of 116 cell cycle genes; whereas,
E2F1 bound to 93 gene promoters, including trp53, ccnb1, wee1,
cdc20 and plk1. These latter data indicate probable transcriptional
interactions between B-MYB and E2F1 in regulating cell cycle
processes in ESCs, while the potential transcriptional interactions
with MYC proteins are somewhat less likely. Perhaps more
importantly, the genes encoding the pluripotency factors, cell cycle
regulators and epigenetic components associated with the global
networks described earlier all show significant and overlapping
promoter binding patterns with each other. B-MYB, for example,
binds to sox2 and nanog, while OSN, E2F1, c-MYC and KLF4 all
bind to the mybl2 gene promoter (Figure 7C).
When compared with known histone methylation sites and
ChIP-seq data from mouse ESCs V 6.5, we found that .80% of
the 1020 B-MYB target genes were H3K4 trimethylated, and that
95% (734) of the 775 informative B-MYB target genes contained
H3K4me3 markers (Figure 7D, Table S9). Conversely, only 93
(9%) putative B-MYB target genes contained H3K27me3 markers,
and only 9 of these had reduced expression following B-MYB
knockdown. Included among the bivalent genes with H3K27me3
marks were known regulators of differentiation and specification
like Gata6, Hoxa6, Hoxa9, and Hoxd11. Importantly, 88.7% of
the OSN and B-MYB co-targeted genes were marked by active
histone methylation (H3K4me3) (Figure 7D), and as described
earlier, most of these had reduced expression in B-MYB
knockdown cells. B-MYB target genes that did not show significant
decreases in expression in the absence of B-MYB (Figure 6D,
Table 3. Connectivity and fold-changes of key regulatory genes in the co-expression networks of mouse ESCs.
Gene symbol Regulator Fold change Connectivity in the control
Connectivity in the
knockdown
Sall4 TF 1.165 959 0
Mybl2 TF 4.815 867 36
Tcf7 TF 1.881 773 0
Lin28 Post-transcriptional 2.955 763 0
Sox2 TF 2.409 521 0
E2f1 TF 1.888 685 211
Eed Epigenetic 1.633 916 471
Smad3 TF 1.056 468 87
Suz12 Epigenetic 1.616 430 213
Phc1 Epigenetic 1.732 193 0
Zfx TF 1.464 477 294
Nanog TF 1.778 464 343
Jmjd2c Epigenetic 1.667 305 223
Oct4 TF 2.501 682 665
Jarid2 Epigenetic 1.645 0 7
Trp53 TF 1.766 0 16
Dnmt3a Epigenetic 1.053 333 352
Stat3 TF 1.224 0 47
Smad1 TF 1.239 14 86
Ctcf TF 1.681 229 326
Tcl1 TF 3.490 148 261
Zfp281 TF 1.676 38 275
Esrrb TF 2.172 139 431
Klf4 TF 1.331 0 293
Jmjd1a Epigenetic 1.385 631 925
Tcf3 TF 1.885 497 806
Rnf2 Epigenetic 1.786 0 392
Ezh2 Epigenetic 2.508 4 404
Dnmt3b Epigenetic 2.393 204 635
c-Myc TF 1.095 186 742
Fold changes are calculated as the ratio of expression between control and B-MYB deficient ESCs. Connectivity is the number of connected genes for each gene on the
network. Green highlights factors with reduced connectivity, while red indicates factors with enhanced connectivity among genes.
doi:10.1371/journal.pone.0042350.t003
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Figure 6. Identification of B-MYB binding sites on gene promoters and corresponding gene expression profiles. A) ChIP-chip analysis
showing the locations and number of B-MYB binding sites (highlighted in yellow shading, n = 4 biological replicas) and corresponding genes on
Chromosome 6 (for details, see Table S6). Binding was determined from promoter regions corresponding to 8 kb upstream and 2 kb downstream of
the 25,500 transcription start sites of the whole mouse genome. B) To determine antibody specificity, ChIP assays of known B-MYB target genes were
performed in ESCs after B-MYB knockdown. Relative to controls, the number of binding events on known target genes cdc2a and ccnb1 was
significantly reduced in B-MYB deficient cells (KD), indicating that the antibody had good specificity for B-MYB. Untr6 – Untranscribed control DNA
sequence. See Methods for experimental details. C) Independent ChIP assays using IgG precipitated chromatin as a control confirming binding of B-
MYB to the promoter regions identified by ChIP-chip for sox2 (two sites), nanog and ezh2. D) Plot of B-MYB target genes (Table S6) with corresponding
microarray expression data taken from Table S1. This plot indicates that B-MYB target genes have expression levels ranging from just detectable to
elevated.
doi:10.1371/journal.pone.0042350.g006
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Table S9) had a preponderance of H3K27me3 markers
(P,0.001).
Discussion
The quintessential stem cell trait of self-renewal requires
coordination of cell cycle progression with fate choices [16]. In
PSCs, differentiation is believed to be actively suppressed by
coincident activating and silencing histone modifications (i.e., a
bivalent gene), and by promoter binding of pluripotency-promot-
ing factors OSN. Here and consistent with our previous report
[27], we demonstrate that B-MYB is a critical regulator of the ESC
cell cycle, as deficiencies in this TF lead to functional defects in S,
G2 and M phases and to transcriptional modulation of genes
involved in the control of all cell cycle phases in ESCs. The results
also show that B-MYB primarily up-regulates gene activity and
specifically regulates, either directly or indirectly, genes encoding
pluripotency factors, chromatin and histone modifiers (including
PcG proteins), signaling molecules, and TFs involved in fate
choices. The altered expression of these targeted genes has
widespread consequences that ultimately affect at least 5.5% of the
entire ESC transcriptome. These results not only link B-MYB to
cell cycle progression and fate decision (i.e, self-renewal), they
demonstrate that B-MYB in conjunction with other pluripotency
factors and DNA modifying enzymes are integral to the network
that maintains ESC homeostasis and the ESC phenotype. More
specifically, it is the coordinated interactions among pluripotency
TFs, histone methylation and B-MYB that maintain the expression
of most B-MYB target genes; however, B-MYB, E2F1 and perhaps
c-MYC, play a preeminent role in the control of DNA replication
and cell cycle progression.
Cell cycle control and self-renewal
In this study, we have begun to unravel the molecular basis for
ESC cell cycle control of self-renewal mediated by B-MYB. By
genome-wide transcriptome profiling, we identified a broad
spectrum of cell cycle genes repressed in B-MYB deficient cells.
Through gene co-expression profiling, we demonstrated that B-
MYB transcriptionally modulates key members of G1 (Ccnd1,
Cdk2), S (Ccne1&2, Ccna1), and G2/M (Cdh1, Cdc20 APC/C)
phases in ES cells, and that co-expression patterns become
uncoupled in B-MYB deficient cells. We also determined that
functional defects observed following loss of B-MYB could be
directly associated with altered expression of key cell cycle
components. Centrosome and spindle defects, for example, may
be due to B-MYB targets associated with CENP-A NAC/CAD
kinetochore complex dysfunction or regulatory protein abnormal-
ities involved in mitosis control (Table S1) [41,42,43].
This study also unveiled a strong association between the
decreased expression of genes regulated by B-MYB with E2F1 and
to a lesser extent c-MYC. A significant reduction in expression of
genes encoding E2F1-5 and DP1,2 (Table S1), as well as a
significant loss in E2F1 network connectivity were observed in B-
MYB deficient cells. B-MYB target gene promoters contained
significantly elevated numbers of E2f binding sites, and a majority
of these genes bound E2F1 TFs [44], including most cell cycle
genes (93 genes; 80% of the total) and all 16 cell cycle pathway
genes targeted by B-MYB (Tables S1 and S10). E2F1, however,
binds to a much broader gene set than B-MYB, and only 68% of
the genes repressed in B-MYB deficient cells bind E2F1 (mouse ES
cell line R14 ChIP-seq comparisons, data not shown). These
findings are consistent with overlapping and cooperative interac-
tions between B-MYB and E2F1 [45,46]. Significant overlap also
exists between gene promoters that bind c-MYC and B-MYB,
including 13 of 16 B-MYB target genes present in the cell cycle
pathway. B-MYB neither binds to the c-myc promoter, nor
significantly alters the abundance of c-Myc in ESCs lacking B-
MYB. It does, however, bind to and modulate the expression of its
co-factor MAX, and c-MYC binds to the mybl2 gene promoter.
Moreover, the connectivity of c-MYC and its rank among hub
genes in the co-expression network are significantly elevated in B-
MYB deficient cells. This increase in connectivity is insufficient to
completely maintain self-renewal processes, as loss of B-MYB leads
to profound cell cycle defects and growth suppression. Moreover,
Table 4. Significantly enriched biological processes and pathways among the informative B-MYB target genes identified from
CHiP-chip and microarrays.
Biological process of gene ontology (GO) Gene number P value FDR
Mitosis 43 7.35E-21 1.28E-17
M phase of mitotic cell cycle 43 1.70E-20 2.97E-17
M phase 51 4.12E-20 7.20E-17
mitotic cell cycle 45 3.53E-18 6.16E-15
cell cycle phase 52 5.09E-18 8.89E-15
cell cycle process 56 3.00E-17 5.24E-14
DNA packaging 29 4.60E-17 8.04E-14
cell cycle 69 1.13E-15 1.94E-12
protein-DNA complex assembly 22 4.65E-13 8.12E-10
chromatin organization 39 3.12E-10 5.45E-07
regulation of transcription 137 5.50E-09 9.61E-06
embryonic morphogenesis 35 1.03E-06 0.0018054
cell fate commitment 18 4.58E-05 0.0800091
cell differentiation 88 1.99E-04 0.3476293
B-MYB target genes were identified by comparisons of the microarray and ChIP-chip datasets. Significance was determined using Fisher’s exact tests (see materials and
Methods). A total 775 target genes expressed in the microarray experiments was analyzed by DAVID based on GO biological processes (P,0.05, FDR,0.5).
doi:10.1371/journal.pone.0042350.t004
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B-MYB promotes an up-regulation of p21Cip1 and p15INK4b and a
down-regulation of p19INK4d; whereas, c-MYC is thought to
repress the activation cell cycle inhibitors p21Cip1 and p27Kip1
[18,25]. Thus, c-MYC like E2F1 serves as an indirect co-regulator
of B-MYB to regulate cell cycle progression and self-renewal
processes, but its mechanism of action appears to be distinct from
B-MYB and insufficient to account for B-MYBs influence on self-
renewal.
The interplay of B-MYB with transcription regulators of
ESC fate
Collectively, our data indicate that B-MYB is implicated in the
control of ESC fate decisions (i.e., differentiate or remain
pluripotent) through combinatorial interactions with pluripoten-
cy-promoting TFs and co-regulators. B-MYB binds to sox2 and
nanog promoter regions, and knockdown of B-MYB results in a
transient decrease in OSN. Moreover, the mybl2 gene promoter
binds all three of these pluripotency TFs (Table S1) [44,47,48],
which together with at least 15 other co-regulators drive the core
pluripotency network. This newly identified gene circuit has broad
implications for ESC biology, particularly since it should be auto-
regulatory and bi-stable. Most members of this gene circuit are
down-regulated in the absence of B-MYB. For example, network
connections with iPSC reprogramming factors Sox2 and Lin28,
were completely lost in B-MYB deficient cells, while that of Klf4
was significantly increased.
The results from this study also distinguish the role of B-MYB
from that of pluripotency-promoting TFs. First, Sall4 is the
Figure 7. B-MYB target genes and possible interactions with pluripotency factors and regulation by histone methylation. A) Overlap
of target genes between B-MYB and other selected TFs (see materials and Methods). Numbers in bold and italic refer to significant overlaps between
two gene groups with p,10210, in bold refers to p,1023, respectively. B) Overlap of binding sites for Oct4, Sox2, Nanog (OSN) and B-MYB, and the
corresponding biological process (GO terms) that were significantly elevated among the overlapping genes. C) Transcription factor binding
interactome of selected genes associated with pluripotency, cell cycle and epigenetic regulation. Each gene is indicated by a circle, and lines
connecting genes indicate TF binding. TF binding is directional, as the color of the line indicates which factor binds to the connected gene promoter.
The data indicate a high level of crosstalk among pluripotency, cell cycle and epigenetic regulators with B-Myb. Data were taken from Table S1. D)
Overlap among B-MYB target genes with OSN (common targets of Oct4, Sox2 and Nanog identified in at least two ES cells) and the state of histone
methylation (H3K4me3, H3K27me3). All target genes used in this analysis were differentially repressed by the B-MYB knockdown based on the
microarray experiment.
doi:10.1371/journal.pone.0042350.g007
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dominant hub gene in the global co-expression networks of control
ESCs (Figure 5A). SALL4 also showed enhanced abundance in B-
MYB deficient cells, but after B-MYB knockdown, all links of Sall4
to the network were completely lost. Importantly, the sall4
promoter is co-occupied by OSN [49,50], but it is not bound by
B-MYB. Since this TF plays a critical role in maintaining mouse
ESC pluripotency through transcriptional activation of Oct4
[49,51,52,53] and as a co-regulator in the core TF-driven
regulatory network [54], Sall4 must serve as an essential, but
indirect bridge linking pluripotency factors to co-expressed genes
regulated by B-MYB. Second, it is also noteworthy that mybl2 and
pou4f1 gene knockouts lead to similar phenotypes in mice, but only
loss of Oct4 in ESCs results in a comparable phenotype in vitro
and in vivo. Both mybl2 and pou4f1 knockouts lead to early
embryonic lethality and loss of ICM. Embryos require B-MYB for
formation of the ICM; however, it is not required for trophecto-
derm formation and expansion [26]. Mouse embryos that are
Oct4-deficient also fail to form ICM, lose pluripotency and
differentiate into trophectoderm. The knockdown phenotype of B-
MYB in vitro is however unique to that of Oct4, Sox2 and Nanog.
Loss of Oct4 in ESCs favors production of trophectoderm
characterized molecularly by the expression of Cdx2, while its
overexpression leads to endoderm formation [55,56]. B-Myb over-
expression has very little effect on mouse ESCs, perhaps due to tight
regulatory mechanisms that prevent elevated levels of B-MYB
proteins in stable clones [57]. By comparison, loss of Nanog
promotes primitive endoderm formation (Gata6 expression), while
loss of Sox2 produces a variety of changes in vitro and fail to develop
an epiblast in vivo [1]. In contrast, knockdown of B-MYB in ESCs
results in either pluripotent and aneuploid cells or a delayed and
transient increase in a variety of differentiation markers (Cdx2,
Hand1 and Sox17) that correlates with increased apoptosis [27].
Third, Oct4, Sox2 and Nanog expression are almost completely
repressed within a few days of in vitro ESC differentiation; whereas,
B-Myb expression becomes tightly coupled to cell cycle regulation.
Moreover, the functional role of B-MYB in pluripotent cells is
unique from its role in differentiated cells. In embryonic carcinoma
cells, B-MYB is constitutively active, but upon differentiation, it
requires the DREAM complex for transcriptional control [58]. The
role of B-MYB in maintaining pluripotency is therefore secondary
to its effects on cell cycle, and it is likely that B-MYB exerts its effects
on pluripotency indirectly through the regulation of other critical
pluripotency factors like SALL4.
The interplay of B-MYB with epigenetic regulators of ESC
fate
A unique and potentially critical finding from this study is the
role of B-MYB in controlling epigenetic regulators of chromatin.
Approximately half of the B-MYB binding sequences identified in
this study are characterized by the presence of RNA Pol II binding
and H3K4me3, and excluding those that contain H3K27me3
marks (i.e., poised DNA), most of these sequences are transcrip-
tionally active. Moreover, 95% of actively transcribed genes are
repressed by knockdown of B-Myb in ESCs. Because H3K4me3
has been proposed as a chromatin mark of transcription initiation
[40,59,60], B-MYB is either involved in activated expression of
target genes or alternatively this mark permits binding of B-MYB
to enhance transcriptional activity. These data, along with
published studies for OSN, c-Myc and E2F1, suggest that these
TFs act coordinately to mediate gene activity that is conducive to
pluripotency, differentiation repression, cell cycle progression and
consequently to the stem cell trait of self-renewal.
The finding that B-MYB regulates the RNA expression of critical
epigenetic regulators (Suv420h2, Phc1, Eed, Ezh2, Jarid2) further
defines a B-MYB regulatory circuit that influences ESC homeostasis
and differentiation. Each factor is involved in histone methylation
events that control fate decisions. Phc1 is a component of polycomb
complex PRC1 that is involved in silencing of developmental genes
[59,61,62], while Jarid2 binds DNA and mediates the recruitment
of the PRC2 complex to target genes, but its inhibition of
methylation plays a key role in differentiation and development
[63,64]. Moreover, Phc1 and Jarid2 act as hub genes in the global
co-expression network conserved between human and mouse ES
cells [65]. EED and EZH2 are major components of the PRC2
complex, which methylates Lys9 and Lys27 of histone H3, to
repress genes like HOXA7, HOXB6 and HOXC8 [66,67,68].
EZH2, in particular, regulates self-renewal processes and prolifer-
ation in stem cells from other systems [69], and its connectivity as
well as that of Jmjd1a and Dnmt3b are significantly increased in B-
MYB deficient cells. Since histone modification levels can be used to
predict gene expression levels [37] and both histone and DNA
methylations are known to be critical for correct differentiation of
ESCs into specific lineages, these findings highlight B-MYB
regulatory interactions among pluripotency TFs and histone
modifiers in promoting gene expression and controlling ESC fate
decisions critical to self-renewal.
Knock-down model system
The functional and bioinformatics data presented in this paper
extend our previously published data that showed punctate and
altered BrdU incorporation during S phase, an accumulation of
cells in G2/M with spindle defects and polyploidy, and changes in
Oct4 abundance. Lorvellec et al. subsequently showed that B-Myb
ablation leads to stalling of replication forks and activation of
replication factories in part due to c-MYC and FOXM1
regulatory mechanisms. These findings are consistent with the
defects in G1 and S phase-associated cell cycle gene expression
that we report here, and our co-expression and promoter analysis
results implicate c-MYC in B-MYB-mediated gene control. In
contrast with our original study and validated RNA data on Oct4
expression, Lorvellec et al. did not observe any influence on oct4
gene regulation by B-MYB. In this model system, however, we
only observed transient decreases in Oct4 and Sox2 following
knockdown of B-Myb, which we originally attributed to the
transient but rapid decrease in B-MYB caused by shRNAs. While
a potential transient loss of Oct4 was not tested by Lorvellec et al.,
the results from their knockout system suggest model differences
that should be considered when interpreting the data presented
here. First, some of the transient effects on pluripotency gene
expression demonstrated here may be secondary to changes in the
proliferation rate and total cell numbers as opposed to the direct
regulation by B-MYB. Second, some differences between the
knockdown and knockout models may be real but model specific.
For example, the acute loss of Rb in mouse embryonic fibroblasts
or cardiomyocytes has been shown to induce cell cycle re-entry
and cell proliferation; however, germline loss or knockout of Rb
does not [70,71]. These differences can be explained, at least
partially, by a functional compensation with other pocket proteins
(p107) present in animal models that does not occur in the cells
[70]; however, neither A-MYB nor C-MYB is abundant in ESCs
[27], suggesting that such a compensatory role is unlikely here.
Third, failure to completely knockdown a gene product using a
knockdown approach would also be expected to differentially
affect gene expression due to reduced but not ablated B-MYB
binding properties to either promoters or protein complexes that
affect individual gene expression. This is possible since the change
in target DNA binding activity, as evidenced by ChIP, is
incomplete. This latter possibility is of particular interest because
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the presence of B-MYB in ESCs is rapidly reduced with
differentiation, suggesting that decreases in expression may affect
fate decisions or the establishment of a definitive cell cycle typical
of somatic cells. Fourth, we have also presented data showing that
some of the effects reported here may be non-specific and
dependent on the shRNA employed. This was not the case for
OSN, since shRNA1, 2 and 5 all caused significant decreases in
their expression; however, the discrepancies seen with p21Cip1
between shRNA1 and shRNA5 suggest that some caution should
be taken when interpreting these results. Finally, it is noteworthy
that we did not reproduce our previous results regarding B-MYB
binding to the oct4 promoter. We attribute this to the use of
different antibodies in the two studies. In fact, the antibody (sc-
725) previously employed was found to be unsuitable in ChIP
analyses by GenPathway (this study); however, the antibody (sc-
724) employed here for ChIP experiments has been successfully
utilized in ChIP assays by other groups studying B-MYB [72].
Since we were unable to show B-MYB binding to the oct4
promoter with sc-724, we conclude that B-MYB does not in fact
bind to the oct4 promoter in mouse. The majority of the data
presented in this paper is, however, consistent with both the
knockdown and knockout reports for B-MYB in ESCs. Thus we
conclude that the bioinformatics analyses and data presented in
this paper are valuable and highly indicative of the functional roles
of B-MYB in PSCs.
Summary and conclusions
B-MYB is present in all mammalian cells in proportion to the
degree of cell proliferation. In embryonic carcinoma and somatic
cells, B-MYB is required for active transcription of G2/M genes
through interactions with the DREAM/LIN Complex [58], and
B-Myb depletion in mouse ESCs results in DNA duplication
defects in S phase [28], aneuploidy and defects during mitosis [27].
While the importance of B-MYB to cell cycle progression in ESCs
has not been disputed, its mechanism of transcriptional control has
been, until now, poorly understood in PSCs. In this study, we have
highlighted the importance of B-MYB in self-renewal and
proposed a model for B-MYB as a key regulator of stem cell
and cell cycle genes (Figure 8). The findings presented here
indicate that B-Myb is absolutely essential for ESC self-renewal
and cell identity through a complex transcriptional network that
affects cell cycle regulators, co-expression networks, apoptosis,
chromatin and histone modifiers, and transcription factors
involved in fate decisions. The self-renewal processes regulated
by B-MYB are therefore pivotal for ESC, and by extension iPSC
homeostasis. Finally, the results from this principally ‘‘omic’’ study
suggest the need for continued experiments designed to function-
ally assess specific pathways linking B-MYB with self-renewal and
differentiation. Of particular interest will be an assessment of when
B-MYB binds these target genes during differentiation and cell
cycle progression and how their activation may affect fate choices.
Other experiments will be required to show how repression of cell
cycle progression in somatic cells is overcome through the
reprogramming process, and specifically how B-MYB activation
and its interactions with the LIN complex foster the generation of
PSCs. These studies should lead to a more profound understand-
ing of self-renewal and how reprogramming fosters the establish-
ment of a PSCs that are therapeutically viable.
Materials and Methods
ESCs and B-MYB deficient cells
The murine R1 ESC line obtained from A Nagy (Toronto) [73]
and the 2D4 iPSC line obtained from K Hochedlinger (Boston)
[74] were cultivated on feeder layers of mouse embryonic
fibroblasts (MEFs) or under feeder free conditions as described
[27,74,75]. All experiments with animals used for the preparation
of MEFs were in accordance with NIH guidelines under the
auspices of the National Institute on Aging Animal Care and Use
Committee approved animal study protocol (193-LCS-mi), which
was reviewed and approved by the committee on 04/22/2010.
The National Institute on Aging animal care & use program is
fully accredited by AAALAC International and operates under an
Animal Welfare Assurance from the Office of Laboratory Animal
Welfare. Plasmid DNA containing shRNA1 (shRNA2 and
shRNA5) specific for B-MYB and non-silencing controls were
introduced into ESC using the Nucleofector mouse ES Cell Kit
from Lonza (Cologne, Germany Cat. No VPH-1001) according to
the manufacturer’s instructions as previously described [27]. After
nucleofection, the cells were plated for 18–24 hours, before the
addition of puromycin. Cells were harvested and prepared for
microarrays, PCR or ChIP analyses 24 hours after the addition of
puromycin (n = 4, biological replicas, for each), unless noted
otherwise. Ccnb1 (Accession no. NM_172301) miR target se-
quences were determined using Invitrogen’s BLOCK-iTTM RNAi
Designer. Three sequences with start positions in the ORF Region
of Ccnb1 mRNA (position 682: GCT ATC CTC ATT GAC
TGG CTA; 744: GTA CAT GAC TGT GTC CAT TAT; and
826: GCC ATG TTT ATT GCA AGC AAA) with a predicted
high probability of knockdown were selected to create the miR
RNAi primers, which were then inserted into the pCDNA6.2-
GW/EmGFP-miR expression vector using BLOCK-iTTM Pol II
miR RNAi Expression Vector kit with EmGFP (Invitrogen).
Plasmid DNA was titrated into ES cells at 5, 10, 15, 20, 30 and
40 mg/26106 cells using the Nucleofector mouse ES Cell Kit as
described, and cells were cultured for 24 hours followed by
selection with 60 mg/ml blasticidin for 24 or 48 hours prior to
being isolated as previously described [27]. By western blot, the
most effective miR construct for Cyclin B1 knockdown was
determined to be miR Ccnb1 682 (30 mg) and this miR was used
for all further Cyclin B1 knockdown functional analysis.
Cell Analyses
For determination of colony cell numbers, ESCs were labeled
with DAPI and visualized using an EVOS-fl microscope (AMG)
and mitotic spindles and centrosomes evaluated as previously
described [27]. DNA cell cycle analysis was measured on
propidium iodide (PI, 10 mg, Sigma)-stained nuclei using a Becton
Dickinson FACs CANTO II. Cell cycle compartments were
deconvoluted from single-parameter DNA histograms of 20,000
cells using Multicycler software. 5-Bromodeoxyuridine (BrdU)
incorporation was achieved in cells pulsed (45 min) with 10 mM
BrdU (Sigma), followed by fixation and incubation with rabbit
polyclonal antibodies p-BMyb(Thr490)(sc-20209), p-
BMyb(Thr497)(sc-20210) or p-BMyb(Ser581)(sc-20211)(Santa
Cruz Biotechnologies) followed by incubated with an Alex Fluor
568 conjugated goat anti-rabbit IgG secondary antibody (Invitro-
gen). Cells were fixed again and then incubated with an Alexa
Fluor 488 conjugated anti-BrdU antibody (Invitrogen), followed
by counterstaining with 1 mg/ml Hoechst 33342 or TOPRO-3.
Imaging was with either a Zeiss LSM-310 Laser Scanning Confocal
Microscope or inverted Zeiss microscope with SPOT camera
imaging system. For flow analyses, ESCs were dissociated with
trypsin and fixed in methanol/acetone (1:1) prior to incubation
with rabbit polyclonal antibodies to phosphorylated forms of B-
MYB. Cells were incubated in Alexa Fluor 488 conjugated goat
anti-rabbit IgG (Invitrogen) and counterstained with 10 mg/ml PI
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containing 1 mg/ml RNAse A prior to flow cytometry as
described [27].
ChIP experiments and data analysis
Chromatin was prepared from ESCs nucleofected with a non-
silencing control or shRNA1 to B-MYB as described 48 hours
after nucleofection and including 24 hours of puromycin selection
[27]. Five commercially available antibodies (Santa Cruz: sc-724,
sc-725, sc-13028, sc-81192; Abcam: ab12296) were tested for their
ability to pull-down B-MYB bound chromatin of two known target
genes: cell division cycle-associated protein 2 (Cdca2) and Cyclin
B1 (Ccnb1). Only one antibody (sc-724) effectively precipitated
chromatin regions containing Cdca2 and Ccnb1 above the
negative control sequence threshold (Untr6) and isotype controls.
Using this antibody, three independent assays from R1 ESCs and
two additional samples from ESCs nucleofected with a shRNA
against B-MYB or non-silencing control and selected with
puromycin were analyzed. For each experiment 56106–16107
cells were fixed by the addition of one-tenth volume of
formaldehyde solution (11% Formaldehyde, 0.1 M NaCl, 1 mM
EDTA pH 8.0, 50 mM HEPES pH 7.9) to the cultivation media,
followed by agitation for 15 minutes at room temperature.
Fixation was stopped by the addition of one twentieth volume
2.5 M glycine for 5 minutes. Cells were then transferred to conical
tubes and kept at 4uC for the remainder of the procedure. After
cooling, cells were centrifuged at 800 g for 10 minutes, and then
re-suspended in 10 mL chilled PBS-lgepal solution (16PBS, 0.5%
lgepal CA-630 (Sigma#I-8896)) and triturated. Following another
centrifugation, 10 mL of chilled PBS-lgepal was added to each
tube, followed by the addition of PMSF in ethanol (Sigma P-7626)
to a final concentration of 1 mM. The cells were centrifuged
again, the supernatant removed, and the cell pellets snap frozen on
dry ice and stored at280uC. All samples with appropriate controls
were shipped to GenPathway Inc (San Diego, CA) who finished
processing the samples for ChIP. Hybridizations were performed
using GeneChip Mouse Promoter 1.0R Arrays (Affymetrix), which
contained information from ,8 kb upstream and 2 kb down-
stream of 25,500 transcription start sites of known mouse
promoter regions.
Briefly, data were generated by GenPathway using a standard
curve of genomic DNA and known copy numbers without
normalization for primer pair efficiency. The binding events per
1000 cells for each genomic region were calculated from an
average of triplicate qPCR runs for each test, and data were
normalized to sequences with no binding to B-MYB (i.e., Untr
regions). Genpathway indicated that changes in factor binding as
low as 1.36 could be reproducibly demonstrated. In these
experiments, only signals with a threshold of 2.2 or greater than
regions not bound by B-MYB were considered positive. Data
reported here were combined from control nucleofections and the
three mouse R1 ESC samples. BED files were analyzed using the
UCSC genome browser and tiling analysis software available from
Figure 8. Model depicting transcriptional interactions between pluripotency factors and cell cycle regulators in the maintenance
and control of fate decisions that regulate choices between self-renewal and differentiation. In the undifferentiated state, B-MYB
promotes high level expression of cell cycle modulators (Green rectangles), pluripotency factors (Yellow ovals) and epigenetic regulators (Purple
ovals) to maintain self-renewal; however, upon loss of B-MYB, the subsequent reduction in these factors promotes fate choices that foster
differentiation and loss of self-renewal processes. Arrows indicated transcriptional control mechanisms involving epigenetic regulation and/or
transcription factor binding, including the postulated indirect effects of B-MYB mediated by SALL4. Colored arrows reflect the transcriptional control
of those genes highlighted within ovals (Blue – B-MYB, E2F1; Green – B-MYB, c-MYC, E2F1; Black – Oct4, SOX2, Nanog). GATA6 and HOX genes (Grey
rectangles) bind B-MYB, but are transcriptionally inactive unless differentiation is initiated.
doi:10.1371/journal.pone.0042350.g008
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Affymetrix. Confirmatory CHiP assays were performed as
previously described [27]. Cis-elements were analyzed using
bioinformatics tools available from Genomatix, Inc (http://www.
genomatix.de/en/index.html, Munich, Germany). Functional
Annotations and Functional Classes (High and Medium Stringen-
cy) were determined with the Database for Annotation, Visual-
ization and Integrated Discovery (DAVID) v6.7 (http://david.
abcc.ncifcrf.gov/) and Ingenuity Systems IPA (Redwood City,
California).
Independent ChIP analyses employing sc-724 were performed
to confirm the ChIP-chip results acquired by GenPathway.
Antibodies to rabbit IgG (Santa Cruz, Cat No. sc-2027) were
employed as a negative control for immunoprecipitation. For data
analyses, we used a fold enrichment protocol described at (http://
www.invitrogen.com/etc/medialib/files/Cell-Culture/XLSs.Par.
85244.File.dat/ChIP_Data_Analysis_Template.xls). In contrast to
the GenPathway protocol, data were normalized relative to IgG
immunoprecipitations and total DNA input as previously
described [27]. All normalizations were defined in step 2 of the
web link listed above, where IgG fold enrichment equals 1.
Through these independent experiments, we were able to confirm
binding of B-MYB to promoter regions for multiple gene targets
that were originally identified by ChIP-chip.
Microarray experiments and data analysis
RNA was prepared from ESCs nucleofected with a non-
silencing control or shRNA to B-MYB as described 48 hours after
nucleofection and including 24 hours of puromycin selection [27].
All subsequent reactions were performed in the NIA Gene
Expression and Genomics Unit and normalized as previously
described [76]. Total RNA was used to generate biotin-labeled
cRNA using the Illumina TotalPrep RNA Amplification Kit.
Double stranded cDNA was incubated and transcribed overnight
to generate single-stranded RNA (cRNA) containing biotin-16-
UTP. A total of 0.75 mg of biotin-labeled cRNA was hybridized at
58uC for 16 hours to Illumina’s Sentrix Mouse Ref-8 Expression
BeadChips (Illumina, San Diego, CA). Each BeadChip has
,25,600 well-annotated RefSeq transcripts with approximately
30-fold redundancy. Labeled cRNA was detected by staining with
streptavidin-Cy3. Hybridized arrays were scanned using an
Illumina BeadStation 5006 Genetic Analysis Systems scanner
and the image data extracted using the Illumina GenomeStudio
software, version 1.1.1.1. Data will be deposited to Gene
Expression Omnibus (GEO) upon manuscript acceptance. The
microarray gene expression data were normalized using the
quantile method. Normalized data were further converted into
log2 ratios of expression values over the average expression value
across all the samples for each probe. The genes differentially
expressed between normal and B-MYB knockdown cells were
identified by a t-test, with the P value adjusted for the false
discovery rate using the Benjamini-Hochberg algorithm. The fold-
change of the gene expression level was measured as the difference
of mean expression levels between control and B-MYB knockdown
cells. Significantly enriched biological processes and pathways
were identified through GSEA analysis [36] and Fisher’s exact
tests [77], based on Gene Ontology (GO) and KEGG database. In
this study, we report GO chart specificity levels 2 and 3 for
biological processes. The significantly enriched regulatory factors
were identified in the same ways, based on the database provided
by the GSEA website (http://www.broadinstitute.org/gsea/
msigdb/). Gene names, unless otherwise indicated, are in
accordance with standard Mouse Genome Informatics Nomen-
clature: http://www.informatics.jax.org/. Genes are listed in
italics, transcripts with the first letter capitalized and proteins in
fully capitalized letters.
qPCR analyses
ES R1 cells were passaged off of feeder layers, and three
independent samples were prepared for each experimental
conditional. 26106 cells were nucleofected with 15 mg of
appropriate plasmid (pSuper, non-silencing (NS) shRNA shRNA1,
shRNA2, shRNA5) as previously described [27]. Briefly, plasmid
DNA was introduced into ESCs using the Nucleofector mouse ES
Cell Kit from Amaxa Biosystems (Cologne, Germany Cat. No
VPH-1001) according to the manufacturer’s instructions. Cells
were harvested for RNA extraction at 48 and 72 hours after
nucleofection (i.e., 24 and 48 hours after selection with 1 mg/ml of
puromycin (Sigma)). RNA was extracted with the RNA mini Kit
(Quiagen), and qPCR was performed with SybrGreen Kit
(Invitrogen) according to the manufacturer’s instructions in
duplicate or triplicate. Primers employed in this study are shown
in Table 5 or were previously reported [27].
Comparative analyses
For more comprehensive analyses, ChIP-seq and ChIP-chip
tiling array data from mouse ES cells for various TFs and histone
methylations were downloaded, and candidate genes whose
promoters were occupied by these regulators identified. The
ChIP-seq data (bed file) were downloaded from the GEO database
of NCBI: GSE1224 for the data contained H3K4me3 and
H3K27me3; GSE 11431 for the data contained 13 TFs (Nanog,
Oct4, STAT3, Smad1, Sox2, Zfx, c-Myc, n-Myc, Klf4, Esrrb,
Tcfcp2l1, E2f1 and CTCF) and two transcription regulators p300
and Suz12. These datasets were generated from the mouse ES cell
line V6.5 [47] and E14 [44], respectively. Further binding targets
of TFs (Nanog, Oct4, Sox2, c-Myc, Tcf3, Klf4, Dax1, Rex1,
Dpf281 and Nac1) and histone methylation (H3K4me3) were
obtained from ChIP-seq experiments on mouse ES cells V6.5 [47]
and from ChIP tiling array experiments on the mouse ES cell line
J1 [48]. Specifically comparisons were performed with ChIP-seq
data of mouse ES cells V 6.5 to evaluate histone methylation
patterns [40,47].
ChIP-seq data in bed format were analyzed by the cisGenome
software (http://www.biostat.jhsph.edu/,hji/cisgenome/index.
htm). The bed data contain chromosome locations for all binding
sequence reads of TFs or histone methylations. We first mapped
the reads or tags of each dataset to the mouse genome (version
mm8). We then measured whether there were binding tags located
at the promoter region within 1000 bp of both upstream and
downstream from the transcriptional start site. Putative binding
targets were defined as promoters bound by TFs and histone
methylation marks were also evaluated. We subsequently identi-
fied the candidate target genes of each TF and histone methylation
in mouse ES cells.
Identification of co-expression gene clusters within
pathways
Conserved and divergent co-expression patterns were identified
from gene expression data of ES cells under control and B-MYB
knockdown conditions, respectively, using a comparative cluster-
ing method [65]. Pathway data were adopted from the KEGG
database (www.genome.ad.jp/kegg). Although a total of 51
pathways showed significant associations with B-MYB, we report
only two gene co-expression patterns essentials to ES cell signaling
pathways: cell cycle and apoptosis.
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Construction of global gene co-expression networks
Global co-expression networks of ESCs were constructed from
microarray data derived under both control and knockdown
conditions. The Pearson correlation coefficient value (r) was first
calculated based on the expression profiles for each gene pair. The
co-expression links in the network were kept if the corresponding r
values are at or above a threshold. The threshold value was
determined according to the scale-free criterion, which is
measured by the square of the correlation coefficient (R) between
log(P(k)) and log (k), where k denotes the connectivity of a node, or
the number of links of a node to other nodes in a network. P(k)
gives the probability that a selected node has exactly k links, which
is calculated as the number of the nodes (genes) at a given k value
divided by the total number of nodes. The R value of 0.80
corresponded to p,0.03, so that was selected as the threshold
value. At or above the threshold value, genes were considered to
be co-expressed and the derived networks obeyed a power law
distribution and were scale-free. Such a scale-free criterion
removed possible spurious co-expression links and so that the
resulting networks are biologically meaningful.
Statistics
Cell data are presented as mean 6 S.E.M., unless indicated
otherwise, and statistical analyses between groups were performed
with an unpaired T test. The statistical significance of overlaps
between target gene sets of different TFs was assessed using a
Fisher’s exact test according to the hypergeometric distribution. To
perform the Fisher’s exact test, we calculated the enrichment level R
of two gene set overlaps based on an hypergeometric distribution as
described in [54]. Specifically, given a total of N genes, if gene sets A
and B contain m and n genes, respectively, and k of them are in
common, then the P value of enrichment is calculated by:
P~
Xmin (m,n)
i~k
m
i
 
N{m
n{i
 
N
n
 
!
The enrichment level of the overlap is calculated by R= kN/(mn). P
values less than 0.05 were considered significant.
Supporting Information
Table S1 Differentially expressed genes (fold-change
$1.5) identified from microarray experiments, their
overlaps with target genes of TFs, and histone modifi-
cations in mouse ESCs. The differentially under- or over-
expressed genes with the fold-change $1.5 were identified in
mouse ES cells R1 by B-Myb knockdown-dependent microarray
experiment. Target genes of B-MYB were identified by ChIP-chip
in ES cells R1. Target genes of TFs and histone modifications were
identified by ChIP-seq or ChIP tilling array on mouse ES cells
E14, J1 and V 6.5 (see methods for details).
(XLS)
Table S2 GSEA to identify pathways that significantly
differ between control and knockdown conditions. A)
Enriched KEGG pathways in response to B-MYB knockdown,
identified by using GSEA, based on 18,097 expressed genes in
ESCs. In this analysis, a total of 18,097 genes were ranked by fold
change of gene expression between the control and B-MYB
knockdown in mouse ES cells R1 (see Materials and Methods).
The ranked genes were then analyzed by GSEA based on Kegg
pathways. The pathways in the table represents enriched ones for
under-expressed gene set after B-MYB knockdown and with
GSEA p value ,0.05 and FDR q value ,0.25. B) Most significant
biological processes associated with B-MYB knockdown induced
over-expressed genes. For these analyses, a total 18,097 genes were
ranked by fold change of gene expression between control and
BMYB knockdown in mouse ESCs based on microarray
experiments (see Methods). Ranked genes were analyzed using
GSEA based on GO biological processes. The biological processes
in the table represents enriched ones with P value of 0 for over-
expressed genes by B-MYB knockdown.
(XLS)
Table 5. Primers used for QPCR detection.
Name
Official
name Fw Rv bp
Ink4b Cdkn2b CGCTGCCACTGGAGATTGA TCGTGCTTGCAGTCTTCCTAGA 90
Cip1 Cdkn1a CAGGCACCATGTCCAATCCT GAGACAACGGCACACTTTGCT 68
GADD45 GADD45 TGCAGAGCAGAAGACCGAAA ACCGTAATGGTGCGCTGACT 90
Skp2 Skp2 TCAGTGGACACCATGCATAGGA ATCCCATCCCCACGTGAA 87
p107 Rbl1 GCAGATGATGACTATTGCCAAAGA GGGTCTGCCCTGAAATGTACTT 84
E2F1 E2F1 CTGGACCACCTGATGAATATCTGTAC CAATGCTACGAAGGTCCTGACA 106
DP-1 Tfdp1 TCTGCCAGTGATTTGAGCAATG GACCCTGGAGCCGCTGTA 81
Dbf4 Dbf4 GCTTCAGAGCCCACAACCTATT GGTCAGGCTCACTTGCATTGA 88
Bub1 Bub1 CAGCATCTTTACCCTGTCCTAGTCA CCACTGTCGCATGGTCAATG 111
Phc1 Phc1 CCATCCACGCCAGAGTTACA TCCTCGACGCTCCATTGG 74
Ezh2 Ezh2 CAAATCTGTTCAGAGGGAGCAAA CACTTACGATGTAGGAAGCAGTCATACT 93
EED EED ATGCACAACACTGACCCATCA GATGCTGCTATCCCTACTGAAACTG 73
Cdc20 Cdc20 ACCTGGAGGTGACCGCTTTA CGGCTGGTTTTCCTTGCTT 85
Plk1 Plk1 AGCCGGCGGCAGTATGTA CTTTTGTGTCTGCGTCTGAGATCT 85
CDK2 CDK2 CCATTCTCACCGTGTCCTTCA AAAGTCTGCCAGCTTGATGGA 85
CycA Ccna2 TGTGAAGATGCCCTGGCTTT TCAAAACTGCCATCCATTGG 95
doi:10.1371/journal.pone.0042350.t005
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Table S3 Enriched transcription factors in response to
B-MYB knockdown in ESCs identified by GSEA. A total
18,097 genes were ranked by fold-change of gene expression
between the control and B-MYB knockdown in mouse ES cells R1
by microarray experiments (see materials and Methods). The
ranked genes were then analyzed by GSEA based on KEGG
pathways. The pathways in the table represents enriched ones for
under-expressed gene set after B-MYB knockdown and with
GSEA p value ,0.05 and FDR q value ,0.25.
(XLS)
Table S4 Co-expression gene clustering in two ESC-
critical pathways. A) Cell cycle pathway. B) Apoptosis pathway.
(XLS)
Table S5 Global co-expression networks in ESCs under
control and B-MYB deficiency conditions. A) Genes
showing high connectivity in the co-expression network of the
control ESCs. B) Genes showing high connectivity in the co-
expression network of B-MYB knockdown ESCs. C) Most
prevalent genes with differential connectivity in the co-expression
networks of the control ESCs. D) Most prevalent genes with
differential connectivity in the co-expression networks of B-MYB
knockdown ESCs. Target genes of Oct4, Sox2, Nanog, c-Myc and
E2f1 were identified by ChIP-seq or ChIP tilling array on mouse
ES cells E14, J1 and V 6.5 (see Materials and Methods). 1-3O, 1-
3S, 1-3N and 1-2M represent target gene of Oct4, Sox2, Nanog
and c-Myc identified at 1-3 ES cell, respectively. B-MYB target
genes were identified by ChIP-chip. KD – knockdown.
(XLS)
Table S6 ChIP-chip datasets derived from hybridiza-
tions to Affymetrix GeneChip Mouse Promoter 1.0R
Arrays.
(XLS)
Table S7 Functional annotations of ChIP-chip determined B-
MyB target genes based on Fisher’s exact tests and GO terms: A)
functional classes with high stringency; B) functional classes – gene
list with high stringency; C) functional classes with medium
stringency; D) functional classes – gene list with medium
stringency.
(XLS)
Table S8 Cis-element analysis of the 1020 gene promoters that
bound B-MYB and predicted frequency of these elements in
genomic and promoter regions.
(XLS)
Table S9 Overlaps between the 775 informative target genes of
B-MYB and target genes of Oct4, Sox2, Nanog, H3K4me3, and
H3K27me3. All 775 genes in the table are B-MYB target genes
identified by ChIP-chip and overlapped with B-MYB knockdown
microarray dataset (18,097 genes) in mouse ES cells R1. Target
genes of Oct4, Sox2, Nanog, H3K4me3, and H3K27me3 were
identified by ChIP-seq or ChIP-chip tilling array on mouse ES
cells E14, J1 and V 6.5 (see Materials and Methods).
(XLS)
Table S10 Pathway-specific genes bound by B-MYB, Oct4,
Sox2, Nanog, c-Myc and E2f1 in mouse ESCs. 1-2O, 1-2S, 1-2N
and 1-2M represent target genes of Oct4, Sox2, Nanog and c-Myc
identified in one and two mouse ES cells, respectively. Target
genes of Oct4, Sox2, Nanog, c-Myc, E2f1, H3K4me3, and
H3K27me3 were identified by ChIP-seq or ChIP tilling array on
mouse ES cells E14, J1 and V 6.5 (see Materials and Methods).
1O, 1S, 1N and 1M represent target gene of Oct4, Sox2, Nanog
and c-Myc identified at one ES cell, respectively. 2O, 2S, and 2N
represent target gene of Oct4, Sox2, Nanog and c-Myc identified
at 2 ES cells, B-MYB target genes were identified by ChIP-chip.
(XLS)
Figure S1 Distribution of connections per node in the co-
expression networks. Nodes are genes and connections are defined
by co-expression between two genes. We calculated the correlation
(r) between each gene according to its expression profile, and
determined links on the network if r was above the threshold value.
Co-expression was defined by a correlation in expression profiles
(r) higher than 0.75, 0.80, 0.85, and 0.90, with p-value of 0.03,
respectively. The distributions at r$0.90 showed non-random
scale-free topology. The X-axis shows the number of connections
(K), and Y-axis shows the number of nodes [N] that have the
corresponding number of connections in the networks of normal
and B-MYB knockdown cells. The numbers are shown on the
log10 scale.
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